Earnings Outlook For Mirum Pharmaceuticals

Mirum Pharmaceuticals (NASDAQ:MIRM) is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement.

Analysts expect Mirum Pharmaceuticals to report an earnings per share (EPS) of $-0.43.

Anticipation surrounds Mirum Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.

New investors should understand that while earnings performance is important, market reactions are often driven by guidance.

Earnings History Snapshot

Last quarter the company missed EPS by $0.05, which was followed by a 2.34% increase in the share price the next day.

Here's a look at Mirum Pharmaceuticals's past performance and the resulting price change:

Quarter

Q2 2024

Q1 2024

Q4 2023

Q3 2023

EPS Estimate

-0.47

-0.48

-0.24

-0.65

EPS Actual

-0.52

-0.54

-0.66

-0.57

Price Change %

2.0%

3.0%

-1.0%

6.0%

Performance of Mirum Pharmaceuticals Shares

Shares of Mirum Pharmaceuticals were trading at $42.0 as of November 08. Over the last 52-week period, shares are up 39.98%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.

Analysts' Perspectives on Mirum Pharmaceuticals

For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Mirum Pharmaceuticals.

The consensus rating for Mirum Pharmaceuticals is Buy, based on 2 analyst ratings. With an average one-year price target of $57.5, there's a potential 36.9% upside.

Comparing Ratings with ...